Status In progress
Process STA 2018
ID number 1188

Provisional Schedule

Expected publication 31 October 2019

Project Team

Project lead Joanne Ekeledo

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews

Consultees

Companies sponsors Novartis (erenumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Migraine Trust
Professional groups Association of British Neurologists
  British Association for the Study of Headache
  Primary Care Neurology Society
  Royal College of Physicians
  UK Clinical Pharmacy Association

Commentators

Comparator companies Allergan (botulinum toxin type A)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups National Hospital for Neurology and Neurosurgery

Timeline

Key events during the development of the guidance:

Date Update
26 September 2019 - 10 October 2019 Final appraisal document
21 August 2019 Committee meeting: 3
24 May 2019 The company (Novartis) has requested that NICE suspend this appraisal because it has provided a new value proposition and further evidence and analyses for consideration. Therefore, the basis for the decision making is likely to change and NICE has agreed to suspend the release of the Final Appraisal Document (FAD). We will provide a further update on the appraisal and associated timelines in due course.
16 April 2019 Committee meeting
25 February 2019 We are writing to provide an update on the appraisal of erenumab for migraine. A high volume of comments have been received in response to the appraisal consultation document. Given this and the importance of ensuring that NICE and the committee have adequate time to fully consider these comments, and where necessary engage with appropriate experts, we have taken the decision to reschedule the discussion of this appraisal. I would like to reassure you that this decision has not been taken lightly. It has been done to ensure that the committee can make the most informed and robust decision for this technology for patients with migraine. NICE has rescheduled the committee meeting to 16 April 2019 (previously scheduled for 14 February 2019).
06 February 2019 A high volume of comments have been received in response to the appraisal consultation document (ACD). Given this and the importance of ensuring that NICE and the committee have adequate time to fully consider these comments, and where necessary engage with appropriate experts, we have taken the decision to reschedule the discussion of this appraisal. This topic will no longer be discussed at the meeting on Thursday 14 February 2019. This decision has not been taken lightly. It has been done to ensure that the committee can make the most informed and robust decision for this technology for patients with migraine. NICE will provide a further update on rescheduled timelines and a new committee date in due course.
10 January 2019 - 31 January 2019 Appraisal consultation: 1
06 December 2018 Committee meeting: 1
18 July 2018 Following an update from the company, this appraisal has been rescheduled. We anticipate that the appraisal will continue later in 2018 and will provide a further update on the timings when more information is available.
01 March 2018 Invitation to participate
22 February 2018 In progress, Referral received 05.12.17 so webpage amended
05 December 2017 Referral
25 May 2017 - 23 June 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance